Skip to Content
Merck
CN

415286

Copper(II) 5,9,14,18,23,27,32,36-octabutoxy-2,3-naphthalocyanine

Dye content 90 %

Synonym(s):

5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine copper(II) salt

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C80H88CuN8O8
CAS Number:
Molecular Weight:
1353.15
NACRES:
NA.23
PubChem Substance ID:
UNSPSC Code:
12352103
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C80H88N8O8.Cu/c1-9-17-41-89-65-49-33-25-26-34-50(49)66(90-42-18-10-2)58-57(65)73-81-74(58)86-76-61-62(70(94-46-22-14-6)54-38-30-29-37-53(54)69(61)93-45-21-13-5)78(83-76)88-80-64-63(71(95-47-23-15-7)55-39-31-32-40-56(55)72(64)96-48-24-16-8)79(84-80)87-77-60-59(75(82-77)85-73)67(91-43-19-11-3)51-35-27-28-36-52(51)68(60)92-44-20-12-4;/h25-40H,9-24,41-48H2,1-8H3;/q-2;+2

SMILES string

CCCCOc1c2ccccc2c(OCCCC)c3c4nc(nc5n6[Cu]n7c(n4)c8c(OCCCC)c9ccccc9c(OCCCC)c8c7nc%10nc(nc6c%11c(OCCCC)c%12ccccc%12c(OCCCC)c5%11)c%13c(OCCCC)c%14ccccc%14c(OCCCC)c%10%13)c13

InChI key

JJIWQZDKAOMTKU-UHFFFAOYSA-N

form

powder

composition

Dye content, 90%

λmax

853 nm

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mattias N D Svensson et al.
Science advances, 6(26), eaba4353-eaba4353 (2020-07-09)
Fibroblast-like synoviocytes (FLS) are joint-lining cells that promote rheumatoid arthritis (RA) pathology. Current disease-modifying antirheumatic agents (DMARDs) operate through systemic immunosuppression. FLS-targeted approaches could potentially be combined with DMARDs to improve control of RA without increasing immunosuppression. Here, we assessed

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service